Browsing Tag
Psyence Biomedical Ltd.
3 posts
What NPX-5’s Phase IIb trial means for the future of oncology-linked mental health treatments
NPX-5 enters Phase IIb trials for cancer-related mental health. Discover what this means for biotech strategy, regulation, and future treatments.
GMP psilocybin manufacturing supports growing psychedelic clinical pipeline
Psyence Biomedical Ltd. exports GMP psilocybin for a Phase IIb cancer trial. Discover what this means for psychedelic medicine and biotech investors.
How Psyence BioMed’s new pharmaceutical-grade ibogaine supply chain reshapes addiction-therapy markets
Psyence Biomedical Ltd., PsyLabs, ibogaine, psychedelics, substance use disorder, pharmaceutical manufacturing